Olanzapine (Zyprexa Relprevv) vs Risperidone (Uzedy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Risperidone (Uzedy)
Marketed by Teva Pharmaceutical Industries and partners
NCT03503318 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 544 participants assigned to placebo, monthly TV-46000, or every-two-month TV-46000. The hard clinical primary endpoint was time to impending relapse, and it was statistically significantly favorable for both monthly treatment (13/183 vs 53/181; p<0.0001) and every-two-month treatment (23/179 vs 53/181; p<0.0001).
Reported efficacy
Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181 (met)
Result source: NCT03503318
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Risperidone (Uzedy) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | —Not posted · NCT00159770 |
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | —Not posted · NCT00159770 |
| PANSS response | —Not posted · NCT00088491 | —Not posted · NCT00159770 |
| PSP, change | —Not posted · NCT00088491 | —Not posted · NCT00159770 |
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | 7.1% vs 29.3%−22.2 vs placeboNCT035033187 other results
|
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Risperidone (Uzedy)
- —Not posted · NCT00159770
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Risperidone (Uzedy)
- —Not posted · NCT00159770
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Risperidone (Uzedy)
- —Not posted · NCT00159770
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Risperidone (Uzedy)
- —Not posted · NCT00159770
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Risperidone (Uzedy)
- 7.1% vs 29.3%−22.2 vs placeboNCT03503318
7 other results
- 12.8% vs 29.3% NCT03503318
- 0.1% vs 0.3% NCT03503318
- 0.1% vs 0.3% NCT03503318
- 7.1% vs 29.3% NCT03503318
- 13.3% vs 29.3% NCT03503318
- 7.1% vs 29.3% NCT03503318
- 12.8% vs 29.3% NCT03503318
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Olanzapine (Zyprexa Relprevv): 4 of 4 rows · Risperidone (Uzedy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) | Risperidone (Uzedy) |
|---|---|---|
| Dropout rate | 54.9%a NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 21.3%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results22.2%q2m NCT03503318 · Phase 3 · monotherapy 22.4%q1m NCT03893825 · Phase 3 · monotherapy 24.7%q2m NCT03893825 · Phase 3 · monotherapy |
| Discontinued due to AEs | 9.8%a NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 2.2%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results1.1%q2m NCT03503318 · Phase 3 · monotherapy 0%q1m NCT03893825 · Phase 3 · monotherapy 1.2%q2m NCT03893825 · Phase 3 · monotherapy |
| Serious AEs | 9.5%a NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 4.4%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results5.6%q2m NCT03503318 · Phase 3 · monotherapy 4.7%q1m NCT03893825 · Phase 3 · monotherapy 6.8%q2m NCT03893825 · Phase 3 · monotherapy |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence | q1ma injection site nodule 6.6% (placebo 3.4%) insomnia 6.6% (placebo 5.6%) injection site pruritus 5.5% (placebo 2.2%) NCT03503318 · Phase 3 · monotherapy show 3 more resultsq2m injection site nodule 7.2% (placebo 3.4%) weight increased 7.2% (placebo 3.4%) injection site pain 6.7% (placebo 6.1%) NCT03503318 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 14 further endpoints in the CSV export.
Risperidone (Uzedy)
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Risperidone (Uzedy)'s landscape